However, the low frequency of the genomic alterations in cell lines has also been observed in other vulnerabilities (e.g., MET mutations in lung cancer or BRCA1/2 in BC), and this fact has not impacted the clinical development of strategies against them. The gene discussed is MET; the disease is lung cancer.